Investment in Alzheimer's disease research for the next generation of adults with Down syndrome will yield health benefits for future generations
Open Access
- 10 September 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (9) , e70348
Abstract
Recent innovations in Alzheimer's disease (AD) treatment highlight critical gaps in knowledge about how to support healthy aging of adults with Down syndrome (DS). RAND researchers updated demographic and epidemiological evidence about the DS population to assess the impact of increased investment in treatment innovations for DS‐associated Alzheimer's disease (DS‐AD). They estimated life expectancy at birth in 2020 to be 55 years, with ≈ 5 years of DS‐AD. They found that the results of investment were dramatic. Between 2020 and 2070, adult years of life are expected to increase by 5 years without any increase in unhealthy years of life with DS‐AD. Caregiving hours for individuals with DS‐AD are expected to be reduced by 40%, which will generate large annual savings. The new evidence underscores the magnitude of the impact that investment in DS‐AD treatments could have for individuals with DS, their families, and caregivers. Highlights: Evidence is sparse about treatment for Down syndrome (DS)‐associated Alzheimer's disease (DS‐AD) and healthy aging of DS adults. This population simulation model estimates DS‐AD caregiving costs at ≈ $1 billion per year. DS‐AD innovations could increase life expectancy by 5 years and reduce caregiving by 40% by 2070. This better forecasting can improve policy and service planning. DS‐AD research investment could yield dramatic gains for individuals and families.Keywords
Funding Information
- National Down Syndrome Society
This publication has 15 references indexed in Scilit:
- The Association between Sex and Risk of Alzheimer’s Disease in Adults with Down SyndromeJournal of Clinical Medicine, 2021
- A Simple Method for Simulating Dementia Onset and Death within an Existing Demographic ModelMedical Decision Making, 2021
- Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)Alzheimer's & Dementia, 2021
- Epidemiology of Dementia and Alzheimer Disease in Individuals With Down SyndromeJAMA Neurology, 2020
- Sex differences in risk of Alzheimer's disease in adults with Down syndromeAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
- Estimation of the number of people with Down syndrome in the United StatesGenetics in Medicine, 2017
- Nurses' experience of caring for people with intellectual disability and dementiaJournal of Clinical Nursing, 2016
- A prospective 14‐year longitudinal follow‐up of dementia in persons with Down syndromeJournal of Intellectual Disability Research, 2013
- The Public Health Impact of Alzheimer's Disease, 2000–2050: Potential Implication of Treatment AdvancesAnnual Review of Public Health, 2002
- Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.American Journal of Public Health, 1998